Drug Database · Clinicians

Ranolazine

Brands (6) Razine, Ranexa, Cartinex…Show all

Anti-anginal (Cytochrome P450 3A Inhibitors; P-Glycoprotein Inhibitors; Cytochrome P450 2D6 Inhibitors; Organic Cation Transporter 2 Inhibitors) US FDA class
Anti-anginal PH FDA category

Rx · Prescription drug12 PH products
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID a624dc7f-921d-4554-a813-f72dca0133c3, version date October 23, 2026 (Ranolazine · Umedica Laboratories USA Inc.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • Ranolazine extended-release tablets is indicated for the treatment of chronic angina.
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE Ranolazine extended-release tablets is indicated for the treatment of chronic angina. Ranolazine extended-release tablets may be used with beta-blockers, nitrates, calcium channel blockers, anti- platelet therapy, lipid-lowering therapy, ACE inhibitors, and angiotensin receptor blockers. Ranolazine extended-release tablets is an antianginal indicated for the treatment of chronic angina.

Contraindications

4 CONTRAINDICATIONS Ranolazine extended-release tablets is contraindicated in patients: Taking strong inhibitors of CYP3A [see Drug Interactions (7.1)] Taking inducers of CYP3A [see Drug Interactions (7.1)] With liver cirrhosis [see Use in Specific Populations (8.6)] Strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin, nelfinavir) (4, 7.1) CYP3A inducers (e.g., rifampin, phenobarbital, St. John's wort) (4, 7.1) Liver cirrhosis (4, 8.6)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

500 mg twice daily and increase to 1,000 mg twice daily, based on clinical symptoms. (2.1)

2.1 Dosing Information

2.1 Dosing Information Initiate ranolazine extended-release tablets dosing at 500 mg twice daily and increase to 1,000 mg twice daily, as needed, based on clinical symptoms. Take ranolazine extended-release tablets with or without meals. Swallow ranolazine extended-release tablets whole; do not crush, break, or chew. The maximum recommended daily dose of ranolazine extended-release tablets is 1,000 mg twice daily.

If a dose of ranolazine extended-release tablets is missed, take the prescribed dose at the next scheduled time; do not double the next dose.

2.2 Dose Modification

2.2 Dose Modification Dose adjustments may be needed when ranolazine extended-release tablets is taken in combination with certain other drugs [see Drug Interactions (7.1)]. Limit the maximum dose of ranolazine extended-release tablets to 500 mg twice daily in patients on moderate CYP3A inhibitors such as diltiazem, verapamil, and erythromycin.

Use of ranolazine extended-release tablets with strong CYP3A inhibitors is contraindicated [see Contraindications (4), Drug Interactions (7.1)]. Use of P-gp inhibitors, such as cyclosporine, may increase exposure to ranolazine extended-release tablets. Titrate ranolazine extended-release tablets based on clinical response [see Drug Interactions (7.1)].

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use Safety and effectiveness have not been established in pediatric patients.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Of the chronic angina patients treated with ranolazine extended-release tablets in controlled studies, 496 (48%) were ≥ 65 years of age, and 114 (11%) were ≥ 75 years of age. No overall differences in efficacy were observed between older and younger patients. There were no differences in safety for patients ≥ 65 years compared to younger patients, but patients ≥ 75 years of age on ranolazine extended-release tablets, compared to placebo, had a higher incidence of adverse events, serious adverse events, and drug discontinuations due to adverse events.

In general, dose selection for an elderly patient should usually start at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease, or other drug therapy.

Dosage forms

Philippines

  • Extended-release tablet: 1 g, 375 mg, 500 mg
  • Extended-release film-coated tablet: 1 g, 500 mg, 750 mg
  • Prolonged-release tablet: 375 mg, 500 mg, 750 mg

Registered products in the Philippines

12 products registered with the Food and Drug Administration (FDA) Philippines list Ranolazine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products12
Philippine FDA-registered products for Ranolazine
Package insert
CartinexRanolazine
500 mg Extended Release TabletAlu/Amber-Colored PVC/PVDC Blister Pack x 10's (Box of 30's)
Rx
Micro Labs LimitedIndia
Brown & Burk Philippines Inc.Importer: Brown & Burk Philippines inc.
DR-XY43998
Dec 16, 2029
Corvizo 1000Ranolazine
1 g Extended-Release Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Zydus Lifesciences LimitedIndia
Zydus Healthcare Philippines Inc.
DRP-16351
Feb 18, 2030
Corvizo 500Ranolazine
500 mg Extended-Release Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Zydus Lifesciences LimitedIndia
Zydus Healthcare Philippines Inc.
DRP-16353
Feb 18, 2030
Corvizo 750Ranolazine
750 mg Extended-Release Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Zydus Lifesciences LimitedIndia
Zydus Healthcare Philippines Inc.
DRP-16352
Feb 18, 2030
RanexaRanolazine
375 mg Prolonged-Release TabletWhite PVC/PVDC Blister Pack x 15’s (Box of 30’s); White PVC/PVDC Blister Pack x 20’s (Box of 60’s and Box of 100’s); White PVC/PVDC Blister Pack x 20’s (Box of 60’s as Physician’s Sample)
Rx
Menarini – Von Heyden GmbHGermany
Importer: A. Menarini Philippines, Inc.
DR-XY43915
Nov 21, 2029
RanexaRanolazine
500 mg Prolonged-Release TabletWhite PVC/PVDC Blister Pack x 15’s (Box of 30’s); White PVC/PVDC Blister Pack x 20’s (Box of 60’s and Box of 100’s); White PVC/PVDC Blister Pack x 20’s (Box of 60’s) as Physician’s Sample
Rx
Menarini – Von Heyden GmbHGermany
Importer: A. Menarini Philippines, Inc.
DR-XY43914
Nov 21, 2029
RanexaRanolazine
750 mg Prolonged-Release TabletWhite PVC/PVDC Blister Pack x 15’s (Box of 30’s); White PVC/PVDC Blister Pack x 20’s (Box of 60’s and Box of 100’s)
Rx
Menarini – Von Heyden GmbHGermany
Importer: A. Menarini Philippines, Inc.
DR-XY43913
Nov 21, 2029
RazineRanolazine
1 g Extended-Release TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Ajanta Pharma LimitedIndia
Ajanta Pharma Philippines, Inc.Importer: Ajanta Pharma Philippines Inc..
DR-XY47935
Apr 18, 2027
RazineRanolazine
375 mg Extended-Release TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Ajanta Pharma LimitedIndia
Ajanta Pharma Philippines, Inc.Importer: Ajanta Pharma Philippines Inc..
DR-XY47936
Apr 18, 2027
RazineRanolazine
500 mg Extended-Release TabletAlu/Alu Blister Pack x 10's Box of 30's
Rx
Ajanta Pharma LimitedIndia
Ajanta Pharma Philippines, Inc.
DR-XY37422
Feb 1, 2030
RazineRanolazine
500 mg Extended-Release TabletAlu/Alu blister pack x 10's (Box of 30's)
Rx
Ajanta Pharma LimitedIndia
Ajanta Pharma Philippines Inc.Importer: Ajanta Pharma Philippines Inc..
DR-XY48262
Aug 8, 2027
RazineRanolazine
500mg Extended-Release TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Ajanta Pharma LimitedIndia
Ajanta Pharma Philippines Inc.Importer: Ajanta Pharma Philippines Inc..
DR-XY48226
Jul 26, 2027

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Ranolazine extended-release tablets is supplied as film-coated, oblong-shaped, extended-release tablets in the following strengths: 500 mg tablets are Yellow color, with RAN500 on one side and plain on other side 1,000 mg tablets are Yellow color, with RAN1000 on one side and plain on other side Extended-release tablets: 500 mg, 1,000 mg.

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • QT interval prolongation: Can occur with ranolazine. Little data available on high doses, long exposure, use with QT interval-prolonging drugs, potassium channel variants causing prolonged QT interval, in patients with a family history of (or congenital) long QT syndrome, or in patients with known acquired QT interval prolongation. (5.1)
  • Renal failure: Monitor renal function after initiation and periodically in patients with moderate to severe renal impairment (CrCL<60 mL/min). If acute renal failure develops, discontinue ranolazine extended-release tablets. (5.2)
5.1 QT Interval Prolongation

5.1 QT Interval Prolongation Ranolazine blocks I Kr and prolongs the QTc interval in a dose-related manner. Clinical experience in an acute coronary syndrome population did not show an increased risk of proarrhythmia or sudden death [see Clinical Studies (14.2)]. However, there is little experience with high doses (>1,000 mg twice daily) or exposure, other QT- prolonging drugs, potassium channel variants resulting in a long QT interval, in patients with a family history of (or congenital) long QT syndrome, or in patients with known acquired QT interval prolongation.

5.2 Renal Failure

5.2 Renal Failure Acute renal failure has been observed in some patients with severe renal impairment (creatinine clearance [CrCL] <30 mL/min) while taking ranolazine extended-release tablets. If acute renal failure develops (e.g., marked increase in serum creatinine associated with an increase in blood urea nitrogen [BUN]), discontinue ranolazine extended-release tablets and treat appropriately [see Use in Specific Populations (8.7)].

Monitor renal function after initiation and periodically in patients with moderate to severe renal impairment (CrCL <60 mL/min) for increases in serum creatinine accompanied by an increase in BUN.

Drug interactions

Drug interactions (US label) US FDA label
  • Moderate CYP3A inhibitors (e.g., diltiazem, verapamil, erythromycin): Limit ranolazine extended-release tablets to 500 mg twice daily. (7.1)
  • P-gp inhibitors (e.g., cyclosporine): Ranolazine exposure increased. Titrate ranolazine extended-release tablets based on clinical response. (7.1)
  • CYP3A substrates: Limit simvastatin to 20 mg when used with ranolazine extended-release tablets. Doses of other sensitive CYP3A substrates (e.g., lovastatin) and CYP3A substrates with narrow therapeutic range (e.g., cyclosporine, tacrolimus, sirolimus) may need to be reduced with ranolazine extended-release tablets. (7.2)
  • OCT2 substrates: Limit the dose of metformin to 1700 mg daily when used with ranolazine extended-release tablets 1,000 mg twice daily. Doses of other OCT2 substrates may require adjusted doses. (7.2)
  • Drugs transported by P-gp (e.g., digoxin), or drugs metabolized by CYP2D6 (e.g., tricyclic antidepressants) may need reduced doses when used with ranolazine extended-release tablets. (7.2)
7.1 Effects of Other Drugs on Ranolazine Strong CYP3A Inhibitors

7.1 Effects of Other Drugs on Ranolazine Strong CYP3A Inhibitors Do not use ranolazine extended-release tablets with strong CYP3A inhibitors, including ketoconazole, itraconazole, clarithromycin, nefazodone, nelfinavir, ritonavir, indinavir, and saquinavir [see Contraindications (4), Clinical Pharmacology (12.3)]. Moderate CYP3A Inhibitors Limit the dose of ranolazine extended-release tablets to 500 mg twice daily in patients on moderate CYP3A inhibitors, including diltiazem, verapamil, erythromycin, fluconazole, and grapefruit juice or grapefruit-containing products [see Dosage and Administration (2.2), Clinical Pharmacology (12.3)].

P-gp Inhibitors Concomitant use of ranolazine extended-release tablets and P-gp inhibitors, such as cyclosporine, may result in increases in ranolazine concentrations. Titrate ranolazine extended-release tablets based on clinical response in patients concomitantly treated with predominant P-gp inhibitors such as cyclosporine [see Dosage and Administration (2.2)].

CYP3A Inducers Do not use ranolazine extended-release tablets with CYP3A inducers such as rifampin, rifabutin, rifapentine, phenobarbital, phenytoin, carbamazepine, and St. John's wort [see Contraindications (4), Clinical Pharmacology (12.3)].

7.2 Effects of Ranolazine on Other Drugs Drugs Metabolized by CYP3A

7.2 Effects of Ranolazine on Other Drugs Drugs Metabolized by CYP3A Limit the dose of simvastatin in patients on any dose of ranolazine extended-release tablets to 20 mg once daily, when ranolazine is co-administered. Dose adjustment of other sensitive CYP3A substrates (e.g., lovastatin) and CYP3A substrates with a narrow therapeutic range (e.g., cyclosporine, tacrolimus, sirolimus) may be required as ranolazine extended-release tablets may increase plasma concentrations of these drugs [see Clinical Pharmacology (12.3)].

Drugs Transported by P-gp Concomitant use of ranolazine and digoxin results in increased exposure to digoxin. The dose of digoxin may have to be adjusted [see Clinical Pharmacology (12.3)]. Drugs Metabolized by CYP2D6 The exposure to CYP2D6 substrates, such as tricyclic antidepressants and antipsychotics, may be increased during co-administration with ranolazine extended-release tablets, and lower doses of these drugs may be required.

Drugs Transported by OCT2 In subjects with type 2 diabetes mellitus, concomitant use of ranolazine extended-release tablets 1,000 mg twice daily and metformin results in increased plasma levels of metformin. When ranolazine extended-release tablets 1,000 mg twice daily is co-administered with metformin, metformin dose should not exceed 1700 mg/day.

Monitor blood glucose levels and risks associated with high exposures of metformin. Metformin exposure was not significantly increased when given with ranolazine extended-release tablets 500 mg twice daily [see Clinical Pharmacology (12.3)].

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

Because ranolazine is a substrate of P-gp, inhibitors of P-gp may increase the absorption of ranolazine.

Metabolism and Excretion Ranolazine is metabolized mainly by CYP3A and, to a lesser extent, by CYP2D6.

Drug Interactions Effect of Other Drugs on ranolazine In vitro data indicate that ranolazine is a substrate of CYP3A and, to a lesser degree, of CYP2D6.

Ranolazine is also a substrate of P-glycoprotein.

Strong CYP3A Inhibitors Plasma levels of ranolazine with ranolazine extended-release tablets 1,000 mg twice daily are increased by 220% when co-administered with ketoconazole 200 mg twice daily [see Contraindications (4) ].

Moderate CYP3A Inhibitors Plasma levels of ranolazine with ranolazine extended-release tablets 1,000 mg twice daily are increased by 50 to 130% by diltiazem 180 to 360 mg, respectively.

Weak CYP3A Inhibitors The weak CYP3A inhibitors simvastatin (20 mg once daily) and cimetidine (400 mg three times daily) do not increase the exposure to ranolazine in healthy volunteers.

CYP3A Inducers Rifampin 600 mg once daily decreases the plasma concentrations of ranolazine (1,000 mg twice daily) by approximately 95% [see Contraindications (4) ].

Adverse reactions

Adverse reactions (US label) US FDA label
  • Most common adverse reactions (>4% and more common than with placebo) are dizziness, headache, constipation, nausea. (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact Umedica Laboratories USA Inc. at 1-855-288-5777 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trial Experience

6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. A total of 2018 patients with chronic angina were treated with ranolazine in controlled clinical trials.

Of the patients treated with ranolazine extended-release tablets, 1026 were enrolled in three double- blind, placebo-controlled, randomized studies (CARISA, ERICA, MARISA) of up to 12 weeks’duration. In addition, upon study completion, 1251 patients received treatment with ranolazine extended-release tablets in open-label, long-term studies; 1227 patients were exposed to ranolazine extended-release tablets for more than 1 year, 613 patients for more than 2 years, 531 patients for more than 3 years, and 326 patients for more than 4 years.

At recommended doses, about 6% of patients discontinued treatment with ranolazine extended-release tablets because of an adverse event in controlled studies in angina patients compared to about 3% on placebo. The most common adverse events that led to discontinuation more frequently on ranolazine extended-release tablets than placebo were dizziness (1.3% versus 0.1%), nausea (1% versus 0%), asthenia, constipation, and headache (each about 0.5% versus 0%).

Doses above ,1,000 mg twice daily are poorly tolerated. In controlled clinical trials of angina patients, the most frequently reported treatment- emergent adverse reactions (>4% and more common on ranolazine extended-release tablets than on placebo) were dizziness (6.2%), headache (5.5%), constipation (4.5%), and nausea (4.4%).

Dizziness may be dose-related. In open-label, long-term treatment studies, a similar adverse reaction profile was observed. The following additional adverse reactions occurred at an incidence of 0.5 to 4.0% in patients treated with ranolazine extended-release tablets and were more frequent than the incidence observed in placebo-treated patients: Cardiac Disorders - bradycardia, palpitations Ear and Labyrinth Disorders - tinnitus, vertigo Eye Disorders - blurred vision Gastrointestinal Disorders - abdominal pain, dry mouth, vomiting, dyspepsia General Disorders and Administrative Site Adverse Events - asthenia, peripheral edema Metabolism and Nutrition Disorders - anorexia Nervous System Disorders - syncope (vasovagal) Psychiatric Disorders - confusional state Renal and Urinary Disorders - hematuria Respiratory, Thoracic, and Mediastinal Disorders - dyspnea Skin and Subcutaneous Tissue Disorders - hyperhidrosis Vascular Disorders - hypotension, orthostatic hypotension Other (<0.5%) but potentially medically important adverse reactions observed more frequently with ranolazine extended-release tablets than placebo treatment in all controlled studies included: angioedema, renal failure, eosinophilia, chromaturia, blood urea increased, hypoesthesia, paresthesia, tremor, pulmonary fibrosis, thrombocytopenia, leukopenia, and pancytopenia.

A large clinical trial in acute coronary syndrome patients was unsuccessful in demonstrating a benefit for ranolazine extended-release tablets, but there was no apparent proarrhythmic effect in these high-risk patients [see Clinical Studies (14.2)]. Laboratory Abnormalities: Ranolazine extended-release tablets produces elevations of serum creatinine by 0.1 mg/dL, regardless of previous renal function, likely because of inhibition of creatinine’s tubular secretion.

In general, the elevation has a rapid onset, shows no signs of progression during long-term therapy, is reversible after discontinuation of ranolazine extended-release tablets, and is not accompanied by changes in BUN. In healthy volunteers, ranolazine extended-release tablets 1,000 mg twice daily had no effect upon the glomerular filtration rate.

More marked and progressive increases in serum creatinine, associated with increases in BUN or potassium, indicating acute renal failure, have been reported after initiation of ranolazine extended-release tablets in patients with severe renal impairment [see Warnings and Precautions (5.2), Use in Specific Populations (8.7)].

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of ranolazine extended-release tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: Nervous System Disorders - Abnormal coordination, myoclonus, paresthesia, tremor, and other serious neurologic adverse events have been reported to occur, sometimes concurrently, in patients taking ranolazine.

The onset of events was often associated with an increase in ranolazine dose or exposure. Many patients reported symptom resolution following drug discontinuation or dose decrease. Metabolism and Nutrition Disorders - Cases of hypoglycemia have been reported in diabetic patients on antidiabetic medication. Psychiatric Disorders - hallucination Renal and Urinary Disorders - dysuria, urinary retention Skin and Subcutaneous Tissue Disorders - angioedema, pruritus, rash

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary There are no available data on ranolazine extended-release tablets use in pregnant women to inform any drug- associated risks. Studies in rats and rabbits showed no evidence of fetal harm at exposures 4 times the maximum recommended human dose (MRHD) (see Data). In the U.S. general population, the estimated background risk of major birth defects and of miscarriage of clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Data Animal Data Embryofetal toxicity studies were conducted in rats and rabbits orally administered ranolazine during organogenesis. In rats, decreased fetal weight and reduced ossification were observed at doses (corresponding to 4-fold the AUC for the MRHD) that caused maternal weight loss. No adverse fetal effects were observed in either species exposed (AUC) to ranolazine at exposures (AUC) equal to the MRHD.

Mechanism of action

12.1 Mechanism of Action The mechanism of action of ranolazine's antianginal effects has not been determined. Ranolazine has anti-ischemic and antianginal effects that do not depend upon reductions in heart rate or blood pressure. It does not affect the rate-pressure product, a measure of myocardial work, at maximal exercise.

Ranolazine at therapeutic levels can inhibit the cardiac late sodium current (I Na). However, the relationship of this inhibition to angina symptoms is uncertain. The QT prolongation effect of ranolazine on the surface electrocardiogram is the result of inhibition of I Kr, which prolongs the ventricular action potential.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics Hemodynamic Effects Patients with chronic angina treated with ranolazine extended-release tablets in controlled clinical studies had minimal changes in mean heart rate (<2 bpm) and systolic blood pressure (<3 mm Hg). Similar results were observed in subgroups of patients with CHF NYHA Class I or II, diabetes, or reactive airway disease, and in elderly patients.

Electrocardiographic Effects Dose and plasma concentration-related increases in the QTc interval [see Warnings and Precautions (5.1)], reductions in T wave amplitude, and, in some cases, notched T waves, have been observed in patients treated with ranolazine extended-release tablets. These effects are believed to be caused by ranolazine and not by its metabolites.

The relationship between the change in QTc and ranolazine plasma concentrations is linear, with a slope of about 2.6 msec/1,000 ng/mL, through exposures corresponding to doses several-fold higher than the maximum recommended dose of 1,000 mg twice daily. The variable blood levels attained after a given dose of ranolazine give a wide range of effects on QTc.

At T max following repeat dosing at 1,000 mg twice daily, the mean change in QTc is about 6 msec, but in the 5% of the population with the highest plasma concentrations, the prolongation of QTc is at least 15 msec. In cirrhotic subjects with mild or moderate hepatic impairment, the relationship between plasma level of ranolazine and QTc is much steeper [see Contraindications (4)].

Age, weight, gender, race, heart rate, congestive heart failure, diabetes, and renal impairment did not alter the slope of the QTc-concentration relationship of ranolazine. No proarrhythmic effects were observed on 7-day Holter recordings in 3162 acute coronary syndrome patients treated with ranolazine extended-release tablets.

There was a significantly lower incidence of arrhythmias (ventricular tachycardia, bradycardia, supraventricular tachycardia, and new atrial fibrillation) in patients treated with ranolazine extended-release tablets (80%) versus placebo (87%), including ventricular tachycardia ≥ 3 beats (52% versus 61%). However, this difference in arrhythmias did not lead to a reduction in mortality, a reduction in arrhythmia hospitalization, or a reduction in arrhythmia symptoms.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

The apparent terminal half-life of ranolazine is 7 hours.

Metabolism and Excretion Ranolazine is metabolized mainly by CYP3A and, to a lesser extent, by CYP2D6.

Following a single oral dose of ranolazine solution, approximately 75% of the dose is excreted in urine and 25% in feces.

Ranolazine is metabolized rapidly and extensively in the liver and intestine; less than 5% is excreted unchanged in urine and feces.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Ranolazine is extensively metabolized in the gut and liver and its absorption is highly variable. For example, at a dose of 1,000 mg twice daily, the mean steady-state C max was 2600 ng/mL with 95% confidence limits of 400 and 6100 ng/mL. The pharmacokinetics of the (+) R- and (-) S-enantiomers of ranolazine are similar in healthy volunteers.

The apparent terminal half-life of ranolazine is 7 hours. Steady state is generally achieved within 3 days of twice-daily dosing with ranolazine extended-release tablets. At steady state over the dose range of 500 to 1,000 mg twice daily, C max and AUC 0-τ increase slightly more than proportionally to dose, 2.2- and 2.4-fold, respectively.

With twice-daily dosing, the trough:peak ratio of the ranolazine plasma concentration is 0.3 to 0.6. The pharmacokinetics of ranolazine is unaffected by age, gender, or food. Absorption and Distribution After oral administration of ranolazine extended-release tablets, peak plasma concentrations of ranolazine are reached between 2 and 5 hours.

After oral administration of 14 C-ranolazine as a solution, 73% of the dose is systemically available as ranolazine or metabolites. The bioavailability of ranolazine from ranolazine extended-release tablets relative to that from a solution of ranolazine is 76%. Because ranolazine is a substrate of P-gp, inhibitors of P-gp may increase the absorption of ranolazine.

Food (high-fat breakfast) has no important effect on the C max and AUC of ranolazine. Therefore, ranolazine extended-release tablets may be taken without regard to meals. Over the concentration range of 0.25 to 10 µg/mL, ranolazine is approximately 62% bound to human plasma proteins. Metabolism and Excretion Ranolazine is metabolized mainly by CYP3A and, to a lesser extent, by CYP2D6.

Following a single oral dose of ranolazine solution, approximately 75% of the dose is excreted in urine and 25% in feces. Ranolazine is metabolized rapidly and extensively in the liver and intestine; less than 5% is excreted unchanged in urine and feces. The pharmacologic activity of the metabolites has not been well characterized.

After dosing to steady state with 500 mg to 1500 mg twice daily, the four most abundant metabolites in plasma have AUC values ranging from about 5 to 33% that of ranolazine, and display apparent half-lives ranging from 6 to 22 hours. Drug Interactions Effect of Other Drugs on ranolazine In vitro data indicate that ranolazine is a substrate of CYP3A and, to a lesser degree, of CYP2D6.

Ranolazine is also a substrate of P-glycoprotein. Strong CYP3A Inhibitors Plasma levels of ranolazine with ranolazine extended-release tablets 1,000 mg twice daily are increased by 220% when co-administered with ketoconazole 200 mg twice daily [see Contraindications (4)]. Moderate CYP3A Inhibitors Plasma levels of ranolazine with ranolazine extended-release tablets 1,000 mg twice daily are increased by 50 to 130% by diltiazem 180 to 360 mg, respectively.

Plasma levels of ranolazine with ranolazine extended-release tablets 750 mg twice daily are increased by 100% by verapamil 120 mg three times daily [see Drug Interactions (7.1)]. Weak CYP3A Inhibitors The weak CYP3A inhibitors simvastatin (20 mg once daily) and cimetidine (400 mg three times daily) do not increase the exposure to ranolazine in healthy volunteers.

CYP3A Inducers Rifampin 600 mg once daily decreases the plasma concentrations of ranolazine (1,000 mg twice daily) by approximately 95% [see Contraindications (4)]. CYP2D6 Inhibitors Paroxetine 20 mg once daily increased ranolazine concentrations by 20% in healthy volunteers receiving ranolazine extended-release tablets 1,000 mg twice daily.

No dose adjustment of ranolazine extended-release tablets is required in patients treated with CYP2D6 inhibitors. Digoxin Plasma concentrations of ranolazine are not significantly altered by concomitant digoxin at 0.125 mg once daily. Effect of ranolazine on Other Drugs In vitro ranolazine and its O-demethylated metabolite are weak inhibitors of CYP3A and moderate inhibitors of CYP2D6 and P-gp.

In vitro ranolazine is an inhibitor of OCT2. CYP3A Substrates The plasma levels of simvastatin, a CYP3A substrate, and its active metabolite are increased by 100% in healthy volunteers receiving 80 mg once daily and ranolazine extended-release tablets 1,000 mg twice daily [see Drug Interactions (7.2)]. Mean exposure to atorvastatin (80 mg daily) is increased by 40% following co-administration with ranolazine extended-release tablets (1,000 mg twice daily) in healthy volunteers.

However, in one subject the exposure to atorvastatin and metabolites was increased by ~400% in the presence of ranolazine extended-release tablets. Diltiazem The pharmacokinetics of diltiazem is not affected by ranolazine in healthy volunteers receiving diltiazem 60 mg three times daily and ranolazine extended-release tablets 1,000 mg twice daily.

P-gp Substrates Ranolazine increases digoxin concentrations by 50% in healthy volunteers receiving ranolazine extended-release tablets 1,000 mg twice daily and digoxin 0.125 mg once daily [see Drug Interactions (7.2)]. CYP2D6 Substrates Ranolazine extended-release tablets 750 mg twice daily increases the plasma concentrations of a single dose of immediate release metoprolol (100 mg), a CYP2D6 substrate, by 80% in extensive CYP2D6 metabolizers with no need for dose adjustment of metoprolol.

In extensive metabolizers of dextromethorphan, a substrate of CYP2D6, ranolazine inhibits partially the formation of the main metabolite dextrorphan. OCT2 Substrates In subjects with type 2 diabetes mellitus, the exposure to metformin is increased by 40% and 80% following administration of ranolazine 500 mg twice daily and 1,000 mg twice daily, respectively.

If co-administered with ranolazine extended-release tablets 1,000 mg twice daily, do not exceed metformin doses of 1700 mg/day [see Drug Interactions (7.2)].

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Ranolazine · Umedica Laboratories USA Inc. [US FDA-approved label, version 2, October 23, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a624dc7f-921d-4554-a813-f72dca0133c3
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .